Proton therapy for early stage breast cancer treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the effects of proton radiation therapy on women with early stage breast cancer. The study compares the outcomes of proton therapy to traditional whole breast irradiation, focusing on the potential benefits of targeting only the tumor site. By limiting radiation exposure to surrounding healthy tissue, the trial seeks to reduce side effects and improve patient convenience and cost-effectiveness. Participants will receive proton therapy as a part of their treatment regimen, and the study will assess both the positive and negative impacts of this approach.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Must sign study-specific, IRB approved informed consent form prior to study entry. Note consent by legally authorized representative is not allowed for this trial.
* Must be female.
* Must be \> = 50 years of age.
* Must have a life expectancy of at least 5 years based on age and co-morbidities.
* Must have pathology proven invasive ductal carcinoma (lobular is not allowed) and/or ductal carcinoma in situ (DCIS).
* One of the following criteria must be met: (a) Tumors that are microscopically multifocal must be 3.0 cm or less in total aggregate size and encompassed within a single scar (b) Patient does not have microscopically multifocal tumor.
* For tumors that are invasive, if in the presence of extensive intraductal component (EIC), the entire pathologic tumor size (including both the intraductal and invasive component) must be 3.0 cm or less.
* Must be Stage 0, I, II (Tis, T1, or T2, N0, M0 per AJCC criteria 7th and/or 8th Ed.). If stage II, the tumor size must be \< = 3.0 cm. A patient with invasive histology must have nodal stage pN0 by H\&E stains on sentinel node biopsy or axillary lymph node dissection.
* Must have ER positive disease with ER/PR report available.
* For tumors that are invasive, HER2 must be performed (positive or negative is acceptable).
* Must have a lumpectomy performed, with documented negative surgical margins by 0.2 cm or more. If re-excision results in negative surgical margins 0.2 cm or more, patient is eligible.
* If image guidance with daily cone beam CT with direct physician visual assessment is used for treatment positioning, the presence of markers or clips in the surgical bed is recommended but not required. If cone beam CT imaging will NOT be used for image guidance, then the patient must be prepared to have 2 fiducial markers minimum, 3 preferred, placed prior to treatment (if not previously done).

  * If markers or clips were placed at the time of surgery, patient must be able to start treatment within 12 weeks after lumpectomy or re-excision for adequate margins.
  * If markers were not placed at the time of surgery and are needed, patient must have markers placed within 6 weeks after surgery.
  * If systemic chemotherapy was given, patient must have had clips or markers placed at the time of surgery (if they are needed) and patient must have simulation scans within 6 weeks of the completion of the chemotherapy.
* Must be able to start treatment within 12 weeks of surgery or 8 weeks of finalization of chemotherapy.

Exclusion Criteria:

* Previous history of ipsilateral invasive breast cancer or DCIS.
* Any clinical or radiographically suspicious nodes, unless biopsy proven benign.
* Non-epithelial malignancies such as sarcoma or lymphoma.
* Suspicious residual microcalcifications on mammography of either breast, unless negative for malignancy on pathology.
* Multicentric or bilateral disease unless biopsy of the clinical abnormalities are performed and result is negative.
* Lymphovascular space invasion (LVSI) on pathology specimen.
* Any previously treated breast carcinoma or synchronous breast carcinoma in ipsilateral breast.
* Prior radiation therapy to the ipsilateral breast or thorax.
* Paget's disease of the nipple.
* Histologic examination showing invasive lobular histology.
* Skin involvement.
* Breasts technically unsatisfactory for radiation treatment upon the discretion of the treating physician.
* Significant infection or other co-existing medical condition that would preclude protocol therapy such as pregnancy, HIV/AIDS or collagen vascular diseases specifically systemic lupus erythematosus, scleroderma, or dermatomyositis.
* Known BRCA 1 or BRCA 2 mutation.
* Pregnant or lactating.

Where it's running

• Mayo Clinic
  Scottsdale, Arizona, United States Recruiting
• California Protons Cancer Therapy Center
  San Diego, California, United States Recruiting
• Northwestern Medicine Chicago Proton Center
  Warrenville, Illinois, United States Recruiting
• Maryland Proton Treatment Center
  Baltimore, Maryland, United States Recruiting
• McLaren Proton Therapy Center
  Flint, Michigan, United States Recruiting
• New York Proton Center
  New York, New York, United States Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• CSF sample collection from people with metastatic breast cancer to see brain metastasis risk

  This study tests whether spinal fluid and other samples can help predict brain metastases in adults with metastatic HER2-positive or triple-negative breast cancer who have not yet shown brain involvement.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07619534

• Precision MRI screening for dense breasts using Prognosia Breast risk score

  This study tests whether using the Prognosia Breast risk score with an MRI for women with very dense breasts and normal mammograms can reduce interval breast cancers.

  Recruiting Washington University School of Medicine · St Louis, Missouri · NCT07277738

• AI-powered mobile app to support chemotherapy for breast cancer

  A mobile app in Arabic uses AI to help women undergoing chemotherapy see if it can improve symptom control and medication adherence compared with standard care.

  Recruiting University of Baghdad · Baghdad · NCT07273812

• ENLIGHT algorithm to find treatment options for advanced metastatic breast cancer

  This test uses the ENLIGHT algorithm to try to find approved drugs that might work better for adults with triple-negative or endocrine therapy–resistant metastatic breast cancer.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07067138

• ChatGPT and surgeon teamwork to improve breast reconstruction consultations

  This project will test whether ChatGPT-generated patient education materials help people preparing for breast reconstruction understand their options and feel more satisfied with their surgeon consultations.

  Recruiting Washington University School of Medicine · St Louis, Missouri · NCT06981208

• Re‑irradiating the breast after a second lumpectomy

  This trial will test whether targeted re‑irradiation (IMRT) after a second lumpectomy is safe for people with ER+ / HER2‑ breast cancer who previously received breast radiation.

  Recruiting at 2 sites Baptist Health South Florida · Boca Raton, Florida and 1 other locations · NCT06867484

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.